首页> 外文期刊>Clinical neuropharmacology >Dysport (botulinum toxin type A) in routine therapeutic usage: A telephone needs assessment survey of european physicians to evaluate current awareness and adherence to product labeling changes
【24h】

Dysport (botulinum toxin type A) in routine therapeutic usage: A telephone needs assessment survey of european physicians to evaluate current awareness and adherence to product labeling changes

机译:常规治疗中的运动障碍(A型肉毒毒素):欧洲医生进行的一项电话需求评估调查,以评估当前对产品标签变更的认识和依从性

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Botulinum neurotoxin type A is a well-established treatment for a number of conditions involving muscle hyperactivity. Dysport (Ipsen Ltd, Wrexham, United Kingdom) is a botulinum neurotoxin type A preparation that has been available for a number of therapeutic uses for over 20 years in the European Union (EU). This survey was part of the EU botulinum toxin risk management plan to identify potential educational needs of injectors by collecting data on their routine practice administration of Dysport and their awareness of potential adverse events (AEs) that are included in the current product labeling. METHODS: Dysport-experienced injectors in 5 EU countries were surveyed via telephone about their experience of Dysport in patients with cervical dystonia, adult upper and lower limb spasticity, pediatric cerebral palsy, and blepharospasm/hemifacial spasm. RESULTS: The reconstitution dilution volume most often used was 2.5 mL per 500 U for all indications. The mean total dose ranged from 387 to 530 U for cervical dystonia, 508 to 773 U for upper limb spasticity, 600 to 832 U for lower limb spasticity, 375 to 700U for pediatric cerebral palsy, and 54 to 213U for blepharospasm/hemifacial spasm. The potential AEs most commonly mentioned by surveyed physicians were dysphagia for cervical dystonia, arm muscle weakness for upper limb spasticity, leg muscle weakness for lower limb spasticity, and pediatric cerebral palsy and ptosis for blepharospasm/hemifacial spasm. CONCLUSIONS: The results indicate that product-labeling recommendations are generally applied in clinical practice and that there is a good familiarity with potential AEs based on clinical condition. Nevertheless, the survey shows that experienced injectors do sometimes deviate from the manufacturers labeling recommendations, highlighting the importance of ongoing education.
机译:背景:A型肉毒杆菌神经毒素是一种针对多种涉及肌肉活动过度的疾病的公认治疗方法。 Dysport(Ipsen Ltd,英国雷克瑟姆,英国)是一种肉毒杆菌神经毒素A型制剂,在欧盟(EU)已有20多年的历史,可用于多种治疗用途。这项调查是欧盟肉毒杆菌毒素风险管理计划的一部分,该计划旨在通过收集有关常规运动管理方面的数据以及当前产品标签中包括的潜在不良事件(AE)的意识,来确定注射器的潜在教育需求。方法:通过电话调查了5个欧盟国家中有运动障碍的注射器对他们的运动障碍在宫颈肌张力障碍,成人上肢和下肢痉挛,小儿脑瘫和眼睑痉挛/半面部痉挛的经历。结果:在所有适应症中,最常用的重构稀释体积为每500 U 2.5 mL。子宫颈肌张力障碍的平均总剂量为387至530 U,上肢痉挛的平均总剂量为508至773 U,下肢痉挛的平均总剂量为600至832 U,小儿脑瘫为375至700 U,眼睑痉挛/半脸痉挛为54至213 U.接受调查的医生最常提及的潜在AE是吞咽困难引起的颈肌张力障碍,手臂肌肉无力引起上肢痉挛,腿部肌肉无力引起下肢痉挛以及小儿脑瘫和上睑下垂引起睑肌痉挛/半脸痉挛。结论:结果表明,产品标签推荐通常用于临床实践,并且根据临床情况对潜在的不良事件已有很好的了解。尽管如此,调查显示,经验丰富的喷油器有时确实会偏离制造商的标签建议,从而突出了进行持续教育的重要性。

著录项

相似文献

  • 外文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号